Mephobarbital

Mephobarbital

SCHEMBL500419

C=CCC1(C(C)CC)C(=O)NC(=O)NC1=O.CCC1(c2ccccc2)C(=O)NC(=O)N(C)C1=O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ

The experimentally established mechanism targets of Mephobarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRB3 known ✓ P28472 4/20 0.44
GABRA1 known ✓ P14867 3/20 0.44
GABRG2 known ✓ P18507 3/20 0.44
GABRB2 known ✓ P47870 3/20 0.44
GABRA2 known ✓ P47869 1/20 0.32
LMNA P02545 2/20 0.61
MMP9 P14780 5/20 0.46
CYP2C19 P33261 2/20 0.43
MMP2 P08253 4/20 0.42
MMP3 P08254 3/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 2/20 0.37
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
APEX1 P27695 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MMP13 P45452 2/20 0.32
CYP3A4 P08684 2/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methohexital SCHEMBL1003787 0.82 LMNA (0.59) LMNAMMP9GABRB3GABRA1GABRG2
Mephobarbital SCHEMBL4266723 0.81 LMNA (0.67) LMNAMMP9GABRB3GABRB2CYP2C19
Mephobarbital SCHEMBL7777123 0.81 LMNA (0.88) LMNAMMP9GABRB3GABRA1GABRG2
(S)-Methylphenobarbital SCHEMBL35625 0.78 LMNA (1.00) LMNAMMP9GABRB3GABRA1GABRG2
Mephobarbital SCHEMBL35624 0.78 LMNA (1.00) LMNAMMP9GABRB3GABRA1GABRG2
(R)-Methylphenobarbital SCHEMBL11789851 0.78 LMNA (1.00) LMNAMMP9GABRB3GABRA1GABRG2
SCHEMBL14788952 0.77 MMP9 (0.50) LMNAMMP9GABRB3GABRA1GABRG2
Mephobarbital SCHEMBL29694125 0.77 LMNA (0.97) LMNAMMP9GABRB3GABRA1GABRG2
Mephobarbital SCHEMBL28475568 0.77 LMNA (0.97) LMNAMMP9GABRB3GABRA1GABRG2
Talbutal SCHEMBL122147 0.76 MMP9 (0.76) LMNAMMP9GABRB3GABRB2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11925707-B2 Co-processed lubricant:MCG for tablets JRS PHARMA GMBH & CO. KG (DE) 2024-03-12 US disclosed
US-20240000798-A1 MODULATION OF SOLUBILITY, STABILITY, ABSORPTION, METABOLISM, AND PHARMACOKINETIC PROFILE OF LIPOPHILIC DRUGS BY STEROLS Marius Pharmaceuticals, Inc. 2024-01-04 US disclosed
WO-2023129540-A1 LUBRICANT FOR PHARMACEUTICALS AND NUTRACEUTICALS JRS PHARMA GMBH & CO. KG (DE) 2023-07-06 WO disclosed
US-20230201124-A1 LUBRICANT FOR PHARMACEUTICALS AND NUTRACEUTICALS JRS PHARMA GMBH & CO. KG (DE) 2023-06-29 US disclosed
US-11617758-B2 Emulsion formulations MARIUS PHARMACEUTICALS LLC (US) 2023-04-04 US disclosed
US-11590146-B2 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols MARIUS PHARMACEUTICALS LLC (US) 2023-02-28 US disclosed
US-20210046087-A1 EMULSION FORMULATIONS Marius Pharmaceuticals, Inc. 2021-02-18 US disclosed
US-20200390784-A1 MODULATION OF SOLUBILITY, STABILITY, ABSORPTION, METABOLISM, AND PHARMACOKINETIC PROFILE OF LIPOPHILIC DRUGS BY STEROLS Marius Pharmaceuticals, Inc. 2020-12-17 US disclosed
US-10576090-B2 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols MARIUS PHARMACEUTICALS LLC (US) 2020-03-03 US disclosed
US-10576089-B2 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols MARIUS PHARMACEUTICALS LLC (US) 2020-03-03 US disclosed
US-20030049208-A1 Over-coated chewing gum formulations WM. WRIGLEY JR. COMPANY 2003-03-13 US disclosed
WO-2002087544-A1 FLAVORED PRODUCT CONTAINING MEDICAMENT OR OTHER ACTIVE AGENT WM. WRIGLEY JR. COMPANY (US) 2002-11-07 WO disclosed
US-20020164398-A1 Method and product for accelerating absorption of medicaments through oral mucosa WM. WRIGLEY JR. COMPANY 2002-11-07 US disclosed
WO-2002071860-A1 GUM BASE AND GUM MANUFACTURING USING PARTICULATED GUM BASE INGREDIENTS L.A. DREYFUS CO. (US) 2002-09-19 WO disclosed
WO-2002069729-A1 GUM BASE AND GUM MANUFACTURING USING PARTICULATED GUM BASE INGREDIENTS L.A. DREYFUS CO. (US) 2002-09-12 WO disclosed
EP-1221863-A1 CHEWING GUM CONTAINING MEDICAMENT ACTIVE AGENTS WM. WRIGLEY JR. COMPANY (US) 2002-07-17 EP disclosed
EP-1139774-A4 IMPROVED RELEASE OF MEDICAMENT ACTIVE AGENTS FROM A CHEWING GUM COATING WRIGLEY W M JUN CO (US) 2002-06-12 EP disclosed
EP-1139774-A1 IMPROVED RELEASE OF MEDICAMENT ACTIVE AGENTS FROM A CHEWING GUM COATING WM. WRIGLEY JR. COMPANY (US) 2001-10-10 EP disclosed
WO-2000035298-A1 CHEWING GUM CONTAINING MEDICAMENT ACTIVE AGENTS WM. WRIGLEY JR. COMPANY (US) 2000-06-22 WO disclosed
WO-2000035296-A1 IMPROVED RELEASE OF MEDICAMENT ACTIVE AGENTS FROM A CHEWING GUM COATING WM. WRIGLEY JR. COMPANY (US) 2000-06-22 WO disclosed